Sunitinib Malate powder Raw Materials CAS 341031-54-7

Related Attributes

Product details

Uses and synthesis of Sunitinib Malate powder

Sunitinib Malate powder is a new oral multi-target anti-tumor drug, belonging to the multi-target tyrosine kinase inhibitor, the product name suntent, which was successfully developed by Pfizer in the United States. Sunitinib Malate has dual anti-tumor effects. Sunitinib Malate is the only drug to break through the 2-year survival of advanced kidney cancer, and has a core position in the treatment of renal cell carcinoma and gastrointestinal stromal tumor. It was launched in the United States in February 2006. Sunitinib Malate is the first anti-cancer drug approved by the United States FDA to treat two diseases at the same time.

Applications/Functions of Sunitinib Malate powder

Sunitinib Malate powder is the first novel targeted drug that can selectively target multiple tyrosine kinase receptors, combining two mechanisms of action: anti-angiogenesis, which interrupts blood supply to tumor cells, and anti-tumor, which directly attacks tumor cells.

Physicochemical Property of Sunitinib Malate powder

Why choose us?

HRK Factory

About Shipping